Berliner Boersenzeitung - Moderna announces positive results for Omicron vaccine

EUR -
AED 3.984481
AFN 76.647787
ALL 100.147252
AMD 420.804469
ANG 1.954129
AOA 946.634516
ARS 1004.781094
AUD 1.640031
AWG 1.95535
AZN 1.847045
BAM 1.952432
BBD 2.189224
BDT 127.400242
BGN 1.954449
BHD 0.408884
BIF 3123.212634
BMD 1.084799
BND 1.458784
BOB 7.492077
BRL 6.046453
BSD 1.08433
BTN 90.766732
BWP 14.731589
BYN 3.548379
BYR 21262.056149
BZD 2.18563
CAD 1.493849
CDF 3071.065425
CHF 0.967533
CLF 0.037148
CLP 1025.123957
CNY 7.891474
CNH 7.908129
COP 4340.247387
CRC 574.409176
CUC 1.084799
CUP 28.747168
CVE 110.075127
CZK 25.411628
DJF 193.086936
DKK 7.46091
DOP 64.219225
DZD 146.325236
EGP 52.461412
ERN 16.271982
ETB 62.673392
FJD 2.440526
FKP 0.835903
GBP 0.840334
GEL 2.94526
GGP 0.835903
GHS 16.730141
GIP 0.835903
GMD 73.522263
GNF 9343.882328
GTQ 8.410492
GYD 226.848699
HKD 8.470028
HNL 26.850684
HRK 7.493736
HTG 143.123121
HUF 390.550892
IDR 17600.860256
ILS 3.931267
IMP 0.835903
INR 90.790987
IQD 1420.449804
IRR 45661.931677
ISK 149.701656
JEP 0.835903
JMD 169.377833
JOD 0.768687
JPY 169.249189
KES 143.733076
KGS 91.520895
KHR 4454.316554
KMF 491.142751
KPW 976.319284
KRW 1503.579939
KWD 0.33171
KYD 0.903541
KZT 513.793735
LAK 24021.564152
LBP 97097.212767
LKR 329.411783
LRD 211.435286
LSL 19.90237
LTL 3.203129
LVL 0.656184
LYD 5.24096
MAD 10.684071
MDL 19.234821
MGA 4918.515837
MKD 61.503909
MMK 3523.384132
MNT 3742.556177
MOP 8.719759
MRU 42.889019
MUR 50.519024
MVR 16.651883
MWK 1880.156835
MXN 19.61512
MYR 5.068197
MZN 69.318632
NAD 19.90237
NGN 1743.272025
NIO 39.911156
NOK 11.986322
NPR 145.226492
NZD 1.822043
OMR 0.417604
PAB 1.08423
PEN 4.074272
PGK 4.248671
PHP 63.455846
PKR 301.863502
PLN 4.279987
PYG 8204.8471
QAR 3.951684
RON 4.972607
RSD 117.071663
RUB 94.561266
RWF 1420.250148
SAR 4.06922
SBD 9.174799
SCR 14.74867
SDG 635.69193
SEK 11.687302
SGD 1.460188
SHP 0.835903
SLE 24.784726
SLL 22747.692057
SOS 619.631171
SRD 31.807347
STD 22453.14461
SVC 9.487634
SYP 2725.589887
SZL 19.898676
THB 39.237187
TJS 11.547581
TMT 3.807644
TND 3.370286
TOP 2.573848
TRY 35.609421
TTD 7.360304
TWD 35.577055
TZS 2912.684789
UAH 44.741723
UGX 4008.086277
USD 1.084799
UYU 43.884302
UZS 13654.446847
VEF 3929740.581046
VES 39.583962
VND 27515.921133
VUV 128.789522
WST 3.041351
XAF 654.827459
XAG 0.037398
XAU 0.000451
XCD 2.931723
XDR 0.817789
XOF 654.827459
XPF 119.331742
YER 271.578928
ZAR 19.9627
ZMK 9764.493785
ZMW 28.109513
ZWL 349.304766
  • RBGPF

    -0.4900

    56.41

    -0.87%

  • CMSC

    -0.0470

    24.223

    -0.19%

  • RYCEF

    0.2700

    5.92

    +4.56%

  • RIO

    -0.5650

    63.425

    -0.89%

  • GSK

    -0.5200

    38.87

    -1.34%

  • BP

    -0.3450

    34.985

    -0.99%

  • BTI

    -0.1250

    33.395

    -0.37%

  • NGG

    0.0020

    62.092

    0%

  • AZN

    -0.2850

    78.875

    -0.36%

  • VOD

    0.0050

    9.075

    +0.06%

  • BCC

    0.6000

    134.56

    +0.45%

  • RELX

    -0.2950

    45.405

    -0.65%

  • CMSD

    -0.0820

    24.408

    -0.34%

  • SCS

    0.0650

    13.925

    +0.47%

  • JRI

    0.0400

    12.57

    +0.32%

  • BCE

    -0.0800

    32.9

    -0.24%

Moderna announces positive results for Omicron vaccine
Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP

Moderna announces positive results for Omicron vaccine

US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.

Text size:

This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.

Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.

Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.

On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.

"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.

"We want to be as ready as early as August for shipping," he told investors in a call.

Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.

The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.

A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.

(T.Burkhard--BBZ)